LEVITRA® (ORAL DISPERSIBLE TABLET) - AN INNOVATIVE DRUG FOR THE TREATMENT OF PATIENTS WITH ERECTILE DYSFUNCTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The arsenal of professionals providing assistance to men with erectile dysfunction includes a new, mouth dissolving dosage form of the vardenafil — levitra* ODT. This form is effective, safe, and has a higher bioavailability as compared to vardenafil in the form of coated tablets. POTENT I and POTENT II studies revealed that levitra* ODT equally successfully corrects erectile dysfunction in men younger and older than 65 years regardless of concomitant diseases and metabolic disorders: hypertension, diabetes, dyslipidemia. In addition, it was found that this drug helped to successfully carry out sexual intercourse in the first 15 minutes after dosing in 62.5% of patients. This allows to widely recommend levitra * ODT for the treatment of erectile dysfunction in young men and older men.

Full Text

Restricted Access

About the authors

I. A Korneyev

Email: iakomeyev@yandex.ru

References

  1. Lue T.F., Tanagho E.A. Physiology of erection and pharmacological management of impotence. J. Urol 1987;137(5):829—836.
  2. Feldman H.A., Goldstein I., Hatzichristou D.G. et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol 1994;;151(1):54—61.
  3. Palmore E.B. Predictors of the longevity difference: a 25-year follow-up. Gerontologist 1982; 22: 513-518.
  4. Persson G. 5-year mortality in a 70-year-old urban population in relation to psychiatric diagnosis, personality, sexuality, and early parent death. Acta Psychiatr. Scand 1981;64: 244-253.
  5. Johannes C.B., Araujo A.B., Feldman H.A. et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J. Urol 2000; Feb;163(2):460-463.
  6. Lewis R.W. Epidemiology of erectile dysfunction. Urol. Clin. North. Am. 2001; May;28(2):209-216
  7. Nehra A., Jackson G., Miner M. et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012; Aug;87(8):766-78.
  8. Marshall B.L. Science, medicine and virility surveillance: 'sexy seniors' in the pharmaceutical imagination Sociol. Health Illn. 2010;32(2):211—224.
  9. Braun M., Wassmer G., Klotz T., et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int. J. Impot. Res. 2000; 12(6):305—311.
  10. Laumann E.O., Paik A., Rosen R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281(6):537—544.
  11. Аль-Шукри С.Х., Корнеев И.А. Сексуальная функция у мужчин с сопутствующими урологическими заболеваниями. Урология 2005; Т. 3:18—22.
  12. Пушкарь Д.Ю., Камалов А.А., Аль-Шукри С.Х. и др. Эпидемиологическое исследование распротраненности эректильной дисфункции в Российской Федерации . Русский медицинский журнал. 2012; 20(3): 112—115.
  13. SatisFACTS. Международний опрос. Байер ХелсКэр, 2011.
  14. Carvalheira A.A., Pereira N.M., Maroco J. et al. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J. Sex. Med. 2012;9(9):2361—2369.
  15. Conaglen H.M., Conaglen J.V. Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. J.Sex.Med.2012;9(3):857—865.
  16. Son H., Park K., Kim S.W. et al. Reasons for discontinuation of sildenafil citrate after successful restoration of erectile function. Asian J. Androl. 2004; 6(2):117—120.
  17. Zitzmann M., Mattern A., Hanisch J. et al. IPASS: A Study on the Tolerability and Effectiveness of Injectable Testosterone Undecanoate for the Treatment of Male Hypogonadism in a Worldwide Sample of 1,438 Men. J Sex Med. 2013; 10(2):579—588.
  18. Корнеев И.А. Практические аспекти назначеним заместительной гормональной терапии тестостероном при возрастном андрогенном дефиците у мужчин. Урология. 2012; 5:122—127.
  19. Hatzichristou D., Rosen R. C., Broderick G. et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004; 1(1):49—57.
  20. Hanash K.A. Comparative results of goal oriented therapy for erectile dysfunction. J. Urol. 1997; 157(6):2135—38.
  21. Hackett G.I. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin. Cornerstone 2005;7(1):57—65.
  22. Jiann B.P., Yu C.C., Su C.C. et al. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int. J. Impot. Res. 2006; 18(2):146—149.
  23. Heinig R., Weimann B., Dietrich H. et al. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials. Clin. Drug Investig. 2011; 31(1):27—41.
  24. Ralph D., Eardley I., Kell P. et al. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int. 2007;100:130—136.
  25. Eardley I., Lee J.C., Shabsigh R. et al. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex. Med. 2010;7:244—255.
  26. Dowson A.J., Charlesworth B.R. Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet. Int. J. Clin. Pract. 2003;57:573—576.
  27. de Argila C.M., Ponce J., Marquez E. et al. Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease: ACEPTO study. Clin. Drug Investig. 2007;27:765—770.
  28. Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int. J. Impot. Res. 2004;16(Suppl. 1):S34—S37.
  29. Sperling H., Debruyne F., Boermans A. et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J. Sex. Med. 2010;7(4 Pt 1):1497—507.
  30. Gittelman M., McMahon C.G., Rodriguez-Rivera J.A. et al. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int. J. Clin. Pract. 2010;64(5):594—603.
  31. Sperling H., Gittelman M., Norenberg C. et al. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials. J. Sex. Med. 2011; 8(1):261—271.
  32. Eardley I., Lee J.C., Guay A.T. Global experiences with vardenafil in men with erectile dysfunction and underlying conditions. Int. J. Clin. Pract. 2008;62(10):1594—603.
  33. Debruyne F.M., Gittelman M., Sperling H. Time to onset of action of vardenafil: a retrospective analysis of the pivotal trials for the orodispersible and film-coated tablet formulations. J. Sex. Med. 2011;8(10):2912—2923.
  34. Ziegler D., Merfort F., van Ahlen H. et al. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J. Sex. Med. 2006;3:883—891.
  35. Stief C., Porst H., Saenz De Tejada I. et al. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int. J. Clin. Pract. 2004;58: 230—239.
  36. Green R., Hicks R.W. Orally disintegrating vardenafil tablets for the treatment of erectile dysfunction: efficacy, safety, and patient acceptability. Patient Prefer. Adherence. 2011;13;5:181—115.
  37. Sanford M. Vardenafil orodispersible tablet. Drugs. 2012; 72(1):87—98.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies